TwitterLinkedin

Contact Us

  • Biopharma Excellence
  • News & Events
    • Industry News Articles
    • Press Releases
    • Webinars
    • Events
    • Blog
    • Podcasts
  • Resource Library
    • Thought Leadership
    • Fact Flyers
    • Case Studies
    • White Papers
    • Webinars
    • Infographics
    • Video & Animation
  • Careers
    • Life at PharmaLex
    • Current Opportunities
  • Training
Top Bar
Search
PharmaLex Logo
MENUMENU
  • PharmaLex Logo
  • PharmaLex Logo
  • About UsAbout Us
    • About Us
    • Management Team
    • Corporate Social Responsibility
    • What Our Clients Say About Us
  • Our Services
    • Discovery / Non-clinical
          • Go to Discovery / Non-clinical section >>

          • Strategy and Consulting

            • Integrated Product Development
            • Market Access
            • Scientific Advice
            • Statistics and Data Sciences
            • Toxicology Services
    • Clinical Development
          • Go to Clinical Development section >>

          • Strategy and Consulting

            • Clinical Program Development
            • Scientific Advice
            • Statistics and Data Sciences
          • Regulatory Affairs

            • Clinical Trial Applications
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Regulatory Operations
          • Pharmacovigilance

            • Clinical Trial Safety Support
            • Pharmacovigilance Consulting
          • Quality

            • GxP Services
            • Interim / Contract QA
            • Quality Management Systems
            • Tech Transfer / Scale-up
    • Authorization / Approval
          • Go to Authorization / Approval section >>

          • Strategy and Consulting

            • Market Access
          • Regulatory Affairs

            • CMC Services
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Marketing and Labeling Activities
            • Regulatory Operations
            • Scientific, Regulatory and Technical Writing
            • Statistics and Data Sciences
          • Pharmacovigilance

            • EU QPPV / National QPPV
            • Pharmacovigilance Consulting
          • Quality

            • Commercialization Readiness
            • Commissioning, Qualification, and Validation (CQV)
            • GxP Services
            • Interim / Contract QA
            • PAI Readiness
    • Post-approval / Maintenance
          • Go to Post-approval / Maintenance section >>

          • Strategy and Consulting

            • Market Access
          • Regulatory Affairs

            • CMC Services
            • Global End-to-End Outsourcing
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Marketing and Labeling Activities
            • Mergers and Acquisitions (M&A) Transfers
            • Regulatory Operations
            • Toxicology Services
          • Pharmacovigilance

            • EU QPPV / National QPPV
            • ICSR (Individual Safety Case Report) Management
            • Literature Monitoring & Screening
            • Pharmacovigilance Quality & Compliance
            • Signal Management
          • Quality

            • Commissioning, Qualification, and Validation (CQV)
            • GxP Services
            • Interim / Contract QA
            • Quality Management Systems
          • Medical Affairs

            • Healthcare Compliance and Medical Approval
    • Program Management
          • Go to Program Management section >>

          • Program Management

            • Global End-to-End Outsourcing
            • Global Procedure Management
            • Integrated Product Development
            • Mergers and Acquisitions (M&A) Transfers
    • Featured Expertise
          • Industry Expertise

            • Biopharmaceuticals
            • MedTech Services
          • Service Expertise

            • ATMP / Cell and Gene Therapy
            • COVID-19 Support
            • GxP Services
            • Market Access
            • Pharmacovigilance Consulting
            • Post-Brexit Regulatory Support
            • Statistics and Data Sciences
            • SMARTPHLEX - technology-enabled services
  • Global ReachGlobal Reach
  • Contact usContact us
  • News & Events
    • Industry News Articles
    • Press Releases
    • Webinars
    • Events
    • Blog
    • Podcasts
  • Resource Library
    • Thought Leadership
    • Fact Flyers
    • Case Studies
    • White Papers
    • Webinars
    • Infographics
    • Video & Animation
  • Careers
    • Life at PharmaLex
    • Career Opportunities
  • Training
Home > News & Events > Blog > TGA will require DOC’s to be submitted for Class I ARTG registrations

TGA will require DOC’s to be submitted for Class I ARTG registrations

Class I ARTG registrations

Author: Luis Jimenez

Australia’s, Therapeutic Goods Administration (TGA) issued a notice on 1 October 2020, in addition to an email to stakeholders prior, specifying new policies for the inclusion of non-sterile, non-measuring Class 1 Medical Devices. These changes include:

  • Enhancements to the application for inclusion in the Australian Register of Therapeutic Goods (ARTG) form; and
  • Modification of the process by which the TGA reviews applications for inclusion in the ARTG.

Types of Class I Medical Devices exempt from these changes

The TGA noted that the changes will not include Class I IVD medical devices, Class I Export Only and Class I IVD Export Only devices.

Changes to existing Class I Medical Device ARTG entries

The notification did not include any changes to already existing Class I Medical Devices.

Targeted Improvements

With these changes, the TGA aims to make it easier for sponsors to provide the required information for TGA to make a registration decision and reduce the need to ask for more information.

What is changing

  • All ARTG applications of Class I Medical Devices will be required to submit an Australian Declaration of Conformity. Sponsors have always been required to hold a DOC on file, but this will now be required to be submitted as part of the application. The TGA has also revised this form to be more user friendly.
  • The change to the assessment process will help the TGA confirm if the product is a medical device, that it is correctly classified, that the device has the appropriate procedures applied to it and that the information is complete and correct.

What is not changing

  • The change on the process will not change the typical approval time of one (1) day. In some cases, it may take up to four (4) business days or longer if selected for an audit.

What TGA’s Declaration of Conformity (DOC) entails

Templates for Declaration of Conformity are found in at the TGA’s website and they vary by classification and conformity assessment route. The DOC for Sponsors of Class I Medical Devices requires the following:

  • Manufacturers Name
  • Business Address
  • Classification Type
  • GMDN Code and term
  • Standards Applied to the Device
  • Name of Medical Devices.
  • Most importantly, they have to provide a confirmation that the Manufacturer meets the Essential Principles and has the Technical Documentation to back it up.

Until now, Class I registrations did not need supplemental application forms other than the ARTG application.

Some Background on Class I Registrations in Australia

According to the latest TGA Annual performance statistics report issued this month Class I registrations increased from 39% to 57% of the total number of medical device ARTG applications (see table 36 from the report). The change aims to streamline this process.

Historically reviews of Class I application were conducted by restricted word reviews which the TGA described as follows:

“Class I medical devices are included on the ARTG following a self-certification being made online by the sponsor through a computer-generated decision process, we undertake post-market compliance reviews for these devices. This previously included restricted word reviews (up until January 2020), where potentially inappropriate Class I device inclusions are identified by the use of specific words indicative of risk, or listing issues relating to the inclusion of the device.

Our current practice is to assess all new Class I ARTG inclusions and request information where there may be uncertainty regarding the appropriateness of the inclusion.”

The report indicated that approximately 413 reviews were triggered this FY compared to 40 in the previous year (see Table 40 below).

Conclusion

The change will help the TGA confirm various factors important to determine if a manufacturer has the appropriate data and is the classification is correct for Class I Medical Device and the anticipated impact of the review is of up to 4 business days, so it should not impact manufacturers much while providing TGA with the ability to better regulate this Class of Medical Devices.

If you have any questions regarding these changes, please reach out, we have a staff of specialised regulatory experts keeping up to date to the current and evolving regulatory environment with regards to the TGA and all major regulatory bodies.

References

TGA Announcement of Changes:
https://www.tga.gov.au/changes-artg-inclusion-process-non-measuring-non-sterile-class-i-medical-devices-0

2020 TGA Annual Statistical Report: https://www.tga.gov.au/sites/default/files/annual-performance-statistics-report-july-2019-june-2020.pdf

Declaration of Conformity Templates:
https://www.tga.gov.au/form/declaration-conformity-templates-medical-devices

Contact us
Related posts
Sponsors gear up for a smoother process with CTIS but must first overcome key hurdles
Sponsors gear up for a smoother process with CTIS but must first overcome key hurdles
2nd June 2022
Medical device software brings new complications around compliance
Medical device software brings new complications around compliance
30th May 2022
Is quality documentation an asset or a burden in regulatory affairs?
Is quality documentation an asset or a burden in regulatory affairs?
6th April 2022
Navigating the impact of the IVDR on marketed products
Navigating the impact of the IVDR on marketed products
24th March 2022
Minimizing risk during the transport of medicinal products
Minimizing risk during the transport of medicinal products
21st March 2022
Next Steps for EUDAMED implementation within MDR
Next Steps for EUDAMED implementation within MDR
7th March 2022
Recent Blogs
  • Sponsors gear up for a smoother process with CTIS but must first overcome key hurdles
    2nd June 2022
  • Medical device software brings new complications around compliance
    30th May 2022
  • Is quality documentation an asset or a burden in regulatory affairs?
    6th April 2022
  • Navigating the impact of the IVDR on marketed products
    24th March 2022
  • Minimizing risk during the transport of medicinal products
    21st March 2022
  • Next Steps for EUDAMED implementation within MDR
    7th March 2022
Recent News
  • Why collaboration and an Integrated Product Development program are key to successful drug development
    14th June 2022
  • Key Takeaways from the PDA Europe Annex 1 Workshop
    7th June 2022
  • Addressing Limitations of Sterility Testing
    9th May 2022
  • Are virtual audits sustainable post-pandemic?
    6th May 2022
  • Orphan Drug Designation: Securing the Significant Benefits
    28th March 2022
  • PharmaLex expands pricing & reimbursement and health economics platform with EBMA Consulting merger
    9th March 2022
Upcoming Webinars

June 28th, 2022

eCTD in Australia: key steps to start a successful submission

08:30 am CET / 4:30 pm AEST

June 28th, 2022

An Introduction to Bayesian adaptive methods in clinical trials

04:00 PM CET

June 30th, 2022

Transforming the drug development process with an integrated strategy

03:00 PM CET

Biopharma Excellence Website Image

PharmaLex Brings You Biopharma Excellence

Biopharma Excellence is a fusion of three scientific powerhouses, PharmaLex, ERA Consulting and Biopharma Excellence – all under the PharmaLex brand. This global team of scientific, regulatory and commercial professionals provide strategic product development and proactive regulatory services to developers of biopharmaceuticals, cell and gene therapies, monoclonal antibodies (MABs), vaccines and biosimilars.

Visit Website
USEFUL LINKS
  • Home
  • Contact us
  • Imprint
  • Data Protection
  • Terms and Conditions
RECENT TWEETS
PharmaLexGLOBALPharmaLex@PharmaLexGLOBAL·
24 Jun

Milena Shuytsova-Mircheva and Lisa Pascoe latest blog here https://www.pharmalex.com/sponsors-gear-up-for-a-smoother-process-with-ctis-but-must-first-overcome-key-hurdles/ discusses the benefit of the Clinical Trial Information System (CTIS).

💡 Interested in CTIS? Take the Phlexglobal survey to evaluate your preparation https://www.phlexglobal.com/ctis-survey

COVID-19 NEWSLETTER SIGN UP

SIGN UP NOW

WHAT OUR CLIENTS SAY
  • Able to explain technical details so non-experts can understand

    US based small / virtual company
    Partner
PharmaLex
©2022 PharmaLex GmbH. All rights reserved.

ISO9001:2015 LogoEnergie Audit LogoSGS Logo

Suspicious Emails

We are aware of a number of suspicious emails about recruitment in circulation purporting to be from PharmaLex. Emails sent by PharmaLex will originate from @pharmalex.com. Should you receive an email and are unsure as to its validity, please report it to contact@pharmalex.com.

Many thanks for your understanding.

The PharmaLex Team

    Please DO NOT send us event/conference information.
    We will not respond and these will be deleted immediately.






    Select your state:

    .
    If you do not wish to receive any communication from us, you may unsubscribe at any time.

    #AskTheExpert #TogetherBEYONDCOVID19





      Select your state:

      .
      You can unsubscribe at any time at data.protection@pharmalex.com

      If you do not wish to receive any communication from us, you can unsubscribe at any time at. Click here to view our Privacy Policy.

      #TogetherBEYONDCOVID19

      We closely monitor developments and updates surrounding the current outbreak of Coronavirus Disease 2019 (COVID-19) from official sources including the World Health Organisation and are following the guidance and direction of the governments and the local authorities. We are taking this situation very seriously and our number one priority is the safety and business continuity for our customers and colleagues. As ever, we will do everything we can to ensure that services are delivered within the required time and the trusted quality PharmaLex is known for